Prophylix AS has just announced that the company in late June 2019 entered into a definitive agreement with Rallybio, a U.S.-based drug development company. Through the agreement Rallybio acquires two orphan drug programs from Prophylix AS, NAITgam and a follow-on therapy. Under the terms of the agreement, Prophylix will receive an undisclosed upfront payment, and is eligible for  development milestones, a percentage of the value of a PRV, if granted, and single to low double digit tiered royalties on sales of NAITgam and the follow-on therapy.

Read more